Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Equity Ratio: 2017-2025

Historic Equity Ratio for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to 0.40.

  • Autolus Therapeutics' Equity Ratio fell 30.43% to 0.40 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.40, marking a year-over-year decrease of 30.43%. This contributed to the annual value of 0.55 for FY2024, which is 83.84% up from last year.
  • Per Autolus Therapeutics' latest filing, its Equity Ratio stood at 0.40 for Q3 2025, which was down 16.55% from 0.48 recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Equity Ratio high stood at 0.86 for Q2 2021, and its period low was 0.30 during Q4 2023.
  • Over the past 3 years, Autolus Therapeutics' median Equity Ratio value was 0.51 (recorded in 2023), while the average stood at 0.51.
  • In the last 5 years, Autolus Therapeutics' Equity Ratio tumbled by 51.25% in 2023 and then spiked by 83.84% in 2024.
  • Autolus Therapeutics' Equity Ratio (Quarterly) stood at 0.77 in 2021, then dropped by 21.15% to 0.61 in 2022, then crashed by 51.25% to 0.30 in 2023, then spiked by 83.84% to 0.55 in 2024, then crashed by 30.43% to 0.40 in 2025.
  • Its last three reported values are 0.40 in Q3 2025, 0.48 for Q2 2025, and 0.50 during Q1 2025.